Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ELI LILLY & Co

Get SEC filing alerts via email and in your feed for ELI LILLY & Co

LLY

ELI LILLY & Co

About ELI LILLY & Co

Eli Lilly and Company is a global pharmaceutical firm focused on discovering, developing, manufacturing, and marketing human medicines. Its core segments include cardiometabolic health, oncology, immunology, and neuroscience, offering products like insulin, diabetes treatments, cancer therapies, and immunomodulators. Serving worldwide markets, Lilly emphasizes innovation, intellectual property protection, and strategic collaborations to deliver value-driven, effective therapies for diverse patient needs.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ELI LILLY & Co

1
1
ELI LILLY & Co Eli Lilly Reports 56% Revenue Growth to $19.8 Billion in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
ELI LILLY & Co Eli Lilly Reports 45% Revenue Growth to $65.2 Billion for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
ELI LILLY & Co Eli Lilly Reports 54% Revenue Growth to $17.6 Billion in Latest Quarter

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
ELI LILLY & Co Eli Lilly Reports 38% Revenue Growth to $15.56 Billion in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ELI LILLY & Co Eli Lilly Reports 45% Revenue Growth to $12.73 Billion in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ELI LILLY & Co Eli Lilly Reports 32% Revenue Growth to $45.04 Billion for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ELI LILLY & Co Eli Lilly Reports 20% Revenue Growth and Significant Net Income Recovery in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments